These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 17379101)

  • 21. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
    Mitsiades CS; Mitsiades NS; Richardson PG; Munshi NC; Anderson KC
    J Cell Biochem; 2007 Jul; 101(4):950-68. PubMed ID: 17546631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogenic or antiestrogenic therapies for multiple myeloma?
    Sola B; Renoir JM
    Mol Cancer; 2007 Sep; 6():59. PubMed ID: 17888187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.
    Siegel DS
    Semin Hematol; 2012 Jul; 49 Suppl 1():S3-15. PubMed ID: 22727390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New horizons in multiple myeloma therapy.
    Santos ES; Kharfan-Dabaja MA
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1483-501. PubMed ID: 17069532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteasome inhibitors in multiple myeloma.
    Anderson KC
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S20-6. PubMed ID: 19393832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melphalan and its role in the management of patients with multiple myeloma.
    Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
    Dmoszynska A; Podhorecka M; Manko J; Bojarska-Junak A; Rolinski J; Skomra D
    Neoplasma; 2005; 52(2):175-81. PubMed ID: 15800717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.
    Yang HH; Ma MH; Vescio RA; Berenson JR
    J Clin Oncol; 2003 Nov; 21(22):4239-47. PubMed ID: 14615454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards a new age in the treatment of multiple myeloma.
    Piazza FA; Gurrieri C; Trentin L; Semenzato G
    Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging strategies for targeting cell adhesion in multiple myeloma.
    Nair RR; Gebhard AW; Emmons MF; Hazlehurst LA
    Adv Pharmacol; 2012; 65():143-89. PubMed ID: 22959026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokines and signal transduction.
    Hideshima T; Podar K; Chauhan D; Anderson KC
    Best Pract Res Clin Haematol; 2005; 18(4):509-24. PubMed ID: 16026734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
    Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
    Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of relapsed and relapsed refractory myeloma.
    Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
    Mitsiades CS; Ocio EM; Pandiella A; Maiso P; Gajate C; Garayoa M; Vilanova D; Montero JC; Mitsiades N; McMullan CJ; Munshi NC; Hideshima T; Chauhan D; Aviles P; Otero G; Faircloth G; Mateos MV; Richardson PG; Mollinedo F; San-Miguel JF; Anderson KC
    Cancer Res; 2008 Jul; 68(13):5216-25. PubMed ID: 18593922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.
    Kumar S; Raje N; Hideshima T; Ishitsuka K; Podar K; Le Gouille S; Chauhan D; Richardson P; Munshi NC; Anderson K
    Br J Haematol; 2006 Mar; 132(6):698-704. PubMed ID: 16487170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
    Orlowski RZ
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.